Protective effects of magnesium lithospermate B against diabetic atherosclerosis via Nrf2-ARE-NQO1 transcriptional pathway.

[1]  A. Bhatnagar,et al.  Aldose Reductase Protects Against Early Atherosclerotic Lesion Formation in Apolipoprotein E–Null Mice , 2009, Circulation research.

[2]  Paul J Thornalley,et al.  Activation of NF-E2–Related Factor-2 Reverses Biochemical Dysfunction of Endothelial Cells Induced by Hyperglycemia Linked to Vascular Disease , 2008, Diabetes.

[3]  Chulhee Choi,et al.  Therapeutic effect of magnesium lithospermate B on neointimal formation after balloon-induced vascular injury. , 2008, European journal of pharmacology.

[4]  D. Ross,et al.  The Highly Expressed and Inducible Endogenous NAD(P)H:quinone Oxidoreductase 1 in Cardiovascular Cells Acts as a Potential Superoxide Scavenger , 2007, Cardiovascular Toxicology.

[5]  D. Hou,et al.  Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin. , 2007, Free radical biology & medicine.

[6]  S. Ylä-Herttuala,et al.  Nrf2 Gene Transfer Induces Antioxidant Enzymes and Suppresses Smooth Muscle Cell Growth In Vitro and Reduces Oxidative Stress in Rabbit Aorta In Vivo , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[7]  T. Cheng.  Danshen: a versatile Chinese herbal drug for the treatment of coronary heart disease. , 2006, International journal of cardiology.

[8]  M. Andrassy,et al.  Protein kinase C beta/early growth response-1 pathway: a key player in ischemia, atherosclerosis, and restenosis. , 2006, Journal of the American College of Cardiology.

[9]  B. Rovin,et al.  Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. , 2006, American journal of physiology. Heart and circulatory physiology.

[10]  T. Cheng.  Danshen: a popular chinese cardiac herbal drug. , 2006, Journal of the American College of Cardiology.

[11]  Zhong Zuo,et al.  Danshen: An Overview of Its Chemistry, Pharmacology, Pharmacokinetics, and Clinical Use , 2005, Journal of clinical pharmacology.

[12]  Michael Brownlee,et al.  The pathobiology of diabetic complications: a unifying mechanism. , 2005, Diabetes.

[13]  Aruni Bhatnagar,et al.  Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. , 2005, Endocrine reviews.

[14]  Masayuki Yamamoto,et al.  Nrf2-Keap1 defines a physiologically important stress response mechanism. , 2004, Trends in molecular medicine.

[15]  George L. King,et al.  Hyperglycemia-induced oxidative stress in diabetic complications , 2004, Histochemistry and Cell Biology.

[16]  L. Berliner,et al.  NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. , 2004, Molecular pharmacology.

[17]  B. Cha,et al.  Delayed treatment with lithospermate B attenuates experimental diabetic renal injury. , 2003, Journal of the American Society of Nephrology : JASN.

[18]  Ruediger C. Braun-Dullaeus,et al.  Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies , 2002, Nature Medicine.

[19]  Joseph L Evans,et al.  Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. , 2002, Endocrine reviews.

[20]  R. Bolli,et al.  Aldose Reductase Is an Obligatory Mediator of the Late Phase of Ischemic Preconditioning , 2002, Circulation research.

[21]  C. Ahn,et al.  Effective isolation of magnesium lithospermate B and its inhibition of aldose reductase and fibronectin on mesangial cell line. , 2002, Chemical & pharmaceutical bulletin.

[22]  M. Brownlee.  Biochemistry and molecular cell biology of diabetic complications , 2001, Nature.

[23]  G. Hart,et al.  Hyperglycemia and the O-GlcNAc transferase in rat aortic smooth muscle cells: elevated expression and altered patterns of O-GlcNAcylation. , 2001, Archives of biochemistry and biophysics.

[24]  C. Bode,et al.  Involvement of aldose reductase in vascular smooth muscle cell growth and lesion formation after arterial injury. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[25]  Y. Kaneda,et al.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.

[26]  S. Yusuf,et al.  Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[27]  P. Klimiuk,et al.  Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. , 1999, The Journal of clinical investigation.

[28]  M. Leon,et al.  The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. , 1998, Journal of the American College of Cardiology.

[29]  T. Uzu,et al.  Translocation of protein kinase C α and ζ in rat glomerular mesangial cells cultured under high glucose conditions , 1994, Diabetologia.

[30]  C. Yabe-Nishimura,et al.  Transcription factor Nrf2 regulates promoter activity of mouse aldose reductase (AKR1B3) gene. , 2005, Journal of pharmacological sciences.